Bausch + Lomb (NYSE:BLCO – Get Free Report) and KORU Medical Systems (NASDAQ:KRMD – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk.
Profitability
This table compares Bausch + Lomb and KORU Medical Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bausch + Lomb | -3.21% | 4.14% | 1.93% |
| KORU Medical Systems | -4.03% | -10.63% | -6.51% |
Risk and Volatility
Bausch + Lomb has a beta of 0.56, suggesting that its stock price is 44% less volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.39, suggesting that its stock price is 61% less volatile than the S&P 500.
Valuation & Earnings
This table compares Bausch + Lomb and KORU Medical Systems”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bausch + Lomb | $5.10 billion | 1.20 | -$360.00 million | ($0.48) | -35.66 |
| KORU Medical Systems | $41.13 million | 3.47 | -$2.64 million | ($0.04) | -77.75 |
KORU Medical Systems has lower revenue, but higher earnings than Bausch + Lomb. KORU Medical Systems is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are held by institutional investors. 1.4% of Bausch + Lomb shares are held by company insiders. Comparatively, 18.5% of KORU Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and price targets for Bausch + Lomb and KORU Medical Systems, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bausch + Lomb | 1 | 7 | 6 | 1 | 2.47 |
| KORU Medical Systems | 1 | 0 | 4 | 1 | 2.83 |
Bausch + Lomb currently has a consensus target price of $19.46, suggesting a potential upside of 13.69%. KORU Medical Systems has a consensus target price of $7.00, suggesting a potential upside of 125.08%. Given KORU Medical Systems’ stronger consensus rating and higher probable upside, analysts clearly believe KORU Medical Systems is more favorable than Bausch + Lomb.
About Bausch + Lomb
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
Receive News & Ratings for Bausch + Lomb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch + Lomb and related companies with MarketBeat.com's FREE daily email newsletter.
